1277097-52-5

Upstream product

• 109-72-8 n-butyllithium 
• 87694-53-9 Boc-Phe-OH N,O-dimethyl hydroxamate 
• 693-03-8 n-butyl magnesium bromide 
• 120125-44-2 N^α-(tert-butoxycarbonyl)-L-phenylalanine-N-morpholinamide 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 

Downstream Products

• 1277097-38-7 tert-butyl (S)-3-oxo-1-phenylheptan-2-ylcarbamate 
• 157394-53-1 tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate 
• 157394-65-5 tert-butyl (2S,3S)-3-hydroxy-1-phenylheptan-2-ylcarbamate 

Relevant academic research and scientific papers

Access to enantiomerically enriched cis-2,3-disubstituted azetidines via diastereoselective hydrozirconation

An asymmetric variant of the hydrozirconation reaction has been established starting from Boc-protected chiral allylic amines. The resulting diastereoselectively formed N-functionalized organozirconiums can be considered as promising chirons. In this case

Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.